{"id":28102,"date":"2022-12-23T08:00:00","date_gmt":"2022-12-23T06:00:00","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/press-releases\/ipsen-receives-complete-response-letter-for-palovarotene-an-investigational-treatment-for-fibrodysplasia-ossificans-progressiva\/"},"modified":"2024-07-23T09:12:36","modified_gmt":"2024-07-23T07:12:36","slug":"ipsen-receives-complete-response-letter-for-palovarotene-an-investigational-treatment-for-fibrodysplasia-ossificans-progressiva","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/ipsen-receives-complete-response-letter-for-palovarotene-an-investigational-treatment-for-fibrodysplasia-ossificans-progressiva\/","title":{"rendered":"Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva"},"content":{"rendered":"\n